Secures KRW 300 million in commercialization funding — “Laying the groundwork to accelerate global expansion”

Bell Therapeutics (CEO Jae Eun Lee) announced on the 17th that it has signed a Memorandum of Understanding (MOU) with Hana Hearing (CEO Dong Hoon Kang), a leading hearing aid specialist chain in Korea, to jointly develop and research a hearing rehabilitation app for hearing aid users.

Digital healthcare startup Bell Therapeutics announced on the 23rd that its digital therapeutic for insomnia, Sleep Thera, has been designated as an Innovative Medical Device (Advanced Technology Category) by the Ministry of Food and Drug Safety (MFDS) of Korea. The recognition comes just two years after the company’s founding.

Bell Therapeutics, a neuroscience-based digital healthcare startup, announced on the 26th that its insomnia digital therapeutic, Sleep Thera, has obtained the European Union (EU) medical device certification, CE MDR.

The digital therapeutics (DTx) startup Bell Therapeutics announced on the 17th that it has been officially selected for the Ministry of SMEs and Startups' private investment-led tech startup support program, "Deep Tech TIPS."

Bell Therapeutics, a startup focused on developing brain science-based digital therapeutics, announced on the 7th that it has partnered with the research consortium "ECHOH" (Enhancing Cognitive Health through Optimal Hearing) to conduct joint research aimed at improving hearing and cognitive health.

The neuroscience-based digital therapeutics startup Bell Therapeutics announced on the 8th that it has received a Good Manufacturing Practice (GMP) certification from the Ministry of Food and Drug Safety for meeting medical device manufacturing and quality management standards.

The neuroscience-based digital therapeutics (DTx) startup Bell Therapeutics announced on the 23rd that it has signed an agreement with the Cochlear Implant Center at Seoul National University Hospital to supply a hearing rehabilitation application (app).

According to industry estimates, around 60 million people globally suffer from severe hearing loss that requires cochlear implant surgery. Severe hearing loss, classified as the inability to hear sounds below 70 decibels, means individuals may not hear a doorbell or knock in a quiet home.

Bell Therapeutics Initiates Clinical Trial for Cochlear Implant Rehabilitation Digital Therapeutic with Professor Choi Byung-Yoon's Team at Seoul National University Bundang Hospital

Bell Therapeutics, a neuroscience-based digital therapeutics company, participated in the Association for Research in Otolaryngology (ARO) conference, where they introduced a music playlist designed to assist cochlear implant users in their auditory rehabilitation.

Bell Therapeutics, a neuroscience-based digital therapeutics (DTx) startup, announced on the 20th that it has secured seed funding from FuturePlay, HGI, and the Korea SMEs and Startups Agency. The investment amount remains undisclosed.

Bell Therapeutics announced on the 21st that it was selected for the Works & Research category at the International Computer Music Conference (ICMC) and showcased a music system designed for people with hearing impairments on the 9th.

Bell Therapeutics, a developer of sonification-based digital therapeutics (DTx), announced on the 17th a multi-faceted partnership with Ewha Womans University's Department of Music Therapy, known for its hospital-centered clinical research.

Bell Therapeutics, a developer of second-generation digital therapeutics (DTx), has partnered with Professor Ki-Young Jung of SNU Hospital's Neurology Department to accelerate product development and clinical research in sleep and neurological disorders.